CORD-19:867ebb2be2d466bcb35e5a7319708eaff39c4799 / 539482-539636 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/867ebb2be2d466bcb35e5a7319708eaff39c4799","sourcedb":"CORD-19","sourceid":"867ebb2be2d466bcb35e5a7319708eaff39c4799","text":"Treatment-emergent adverse event (TEAE) rates for tedizolid and linezolid were 49.7% and 45.8%, and drug-related TEAEs were 20.9% and 15.8%, respectively.","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T65","span":{"begin":0,"end":154},"obj":"Sentence"}],"attributes":[{"subj":"T65","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"T94609","span":{"begin":0,"end":154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T94609","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#93ece6","default":true},{"id":"CORD-19-Sentences","color":"#eccc93"}]}]}}